why choose us

First received: November 22, 2023

Clinical Trial: Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sickle Cell Disease

Study Type: INTERVENTIONAL


Official Title: Non-myeloablative Phase I/II Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Brief Summary: Background:Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels.As a result, affected patients can experience severe pain and serious organ damage.SCD can be cured with a hematopoietic cell transplant (HCT), that is, when they receive blood stem cells from a family donor.But HCT can also have serious side effects, especially in people with organ damage.Researchers want to find ways to make HCT safer for everyone.Objective:To…

Read more